Clinic Roundup
• Biota Pharmaceuticals Inc., of Alpharetta, Ga., began dosing in a Phase II trial of laninamir octanoate, for influenza A or B infection.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.